CN112040983A - 淀粉样变性的治疗和预防 - Google Patents

淀粉样变性的治疗和预防 Download PDF

Info

Publication number
CN112040983A
CN112040983A CN201980028739.4A CN201980028739A CN112040983A CN 112040983 A CN112040983 A CN 112040983A CN 201980028739 A CN201980028739 A CN 201980028739A CN 112040983 A CN112040983 A CN 112040983A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980028739.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·尼杰尔
P·J·多兰三世
R·巴博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puroce Na Bioscience Ltd
Prothena Biosciences Ltd
Original Assignee
Puroce Na Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puroce Na Bioscience Ltd filed Critical Puroce Na Bioscience Ltd
Publication of CN112040983A publication Critical patent/CN112040983A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980028739.4A 2018-03-23 2019-03-22 淀粉样变性的治疗和预防 Pending CN112040983A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
US62/647,341 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
CN112040983A true CN112040983A (zh) 2020-12-04

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980028739.4A Pending CN112040983A (zh) 2018-03-23 2019-03-22 淀粉样变性的治疗和预防

Country Status (13)

Country Link
US (1) US20210017278A1 (https=)
EP (1) EP3768311A1 (https=)
JP (1) JP7217287B2 (https=)
KR (1) KR20200143400A (https=)
CN (1) CN112040983A (https=)
AU (2) AU2019240413A1 (https=)
BR (1) BR112020019172A2 (https=)
CA (1) CA3095100A1 (https=)
EA (1) EA202092264A1 (https=)
MX (1) MX2020009920A (https=)
MY (1) MY203432A (https=)
SG (1) SG11202009295YA (https=)
WO (1) WO2019183448A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202432A1 (en) * 2007-12-28 2009-08-13 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
CN104023743A (zh) * 2011-10-25 2014-09-03 昂克雷夫治疗有限公司 抗体制剂和方法
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202432A1 (en) * 2007-12-28 2009-08-13 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
CN104023743A (zh) * 2011-10-25 2014-09-03 昂克雷夫治疗有限公司 抗体制剂和方法
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONATHAN S. WALL: "AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils", PLOS ONE, vol. 7, no. 12, pages 1 - 10 *
MARK RENZ 等: "2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosisy", AMYLOID, vol. 23, no. 3, pages 168, XP055708123, DOI: 10.1080/13506129.2016.1205974 *
王棪嫒 等: "原发系统性淀粉样变性的诊疗进展", 临床血液学杂志, vol. 29, no. 7, pages 544 - 546 *

Also Published As

Publication number Publication date
EP3768311A1 (en) 2021-01-27
MY203432A (en) 2024-06-27
CA3095100A1 (en) 2019-09-26
BR112020019172A2 (pt) 2021-01-26
KR20200143400A (ko) 2020-12-23
AU2023202109A1 (en) 2023-05-18
EA202092264A1 (ru) 2020-12-03
JP7217287B2 (ja) 2023-02-02
WO2019183448A1 (en) 2019-09-26
AU2019240413A1 (en) 2020-10-08
MX2020009920A (es) 2020-12-10
US20210017278A1 (en) 2021-01-21
JP2021518393A (ja) 2021-08-02
SG11202009295YA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US20230056881A1 (en) TARGETED TGFß INHIBITION
CN113631577B (zh) 抗滋养细胞表面抗原2(trop2)的抗体及包含其的抗体-药物偶联物
CN113512120B (zh) 双特异性四价抗体及其制造和使用方法
AU2022202649A1 (en) Antibody formulations and methods
CN114984227A (zh) 抗tigit抗体在联合用药中的应用
CN116964101A (zh) 结合npr1激动剂的免疫球蛋白
CN112040983A (zh) 淀粉样变性的治疗和预防
US20250249111A1 (en) Eribulin-based antibody-drug conjugates and methods of use
CN115141278A (zh) 抗vista抗体及其应用
HK40079898A (en) Use of anti-tigit antibodies in combination drug
HK40063743B (zh) 抗滋养细胞表面抗原2(trop2)的抗体及包含其的抗体-药物偶联物
HK40080391A (en) Use of anti-tigit antibody in the treatment of tumor or cancer
HK40063743A (en) Anti-trophoblast cell surface antigen 2 (trop2) antibodies and antibody drug conjugates comprising same
CN110785186A (zh) 用于治疗免疫性血小板减少的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination